{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:16:46Z","timestamp":1790705806633,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000869","name":"Susan G. Komen for the Cure","doi-asserted-by":"publisher","award":["KG111237"],"award-info":[{"award-number":["KG111237"]}],"id":[{"id":"10.13039\/100000869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["12POST11760014"],"award-info":[{"award-number":["12POST11760014"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["CA006927"],"award-info":[{"award-number":["CA006927"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["CA083638"],"award-info":[{"award-number":["CA083638"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["CA136596"],"award-info":[{"award-number":["CA136596"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["CA151374"],"award-info":[{"award-number":["CA151374"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["CA158881"],"award-info":[{"award-number":["CA158881"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["T32-CA121938"],"award-info":[{"award-number":["T32-CA121938"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001282","name":"Ovarian Cancer Research Fund","doi-asserted-by":"publisher","award":["258835"],"award-info":[{"award-number":["258835"]}],"id":[{"id":"10.13039\/100001282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA102310"],"award-info":[{"award-number":["CA102310"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.ygyno.2014.04.044","type":"journal-article","created":{"date-parts":[[2014,4,27]],"date-time":"2014-04-27T09:45:38Z","timestamp":1398591938000},"page":"104-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Analyses of merlin\/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer"],"prefix":"10.1016","volume":"134","clinical-trial-number":[{"clinical-trial-number":"nct01778803","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01870609","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nina R.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8626-3263","authenticated-orcid":false,"given":"Isabelle","family":"Tancioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy K.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian J.","family":"Sulzmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Uryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichol L.G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise C.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Schlaepfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.04.044_bb0005","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/GRF.0b013e31824b45da","article-title":"First-line chemotherapy in epithelial ovarian cancer","volume":"55","author":"Bookman","year":"2012","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0025","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1158\/0008-5472.CAN-11-3911","article-title":"The changing view of high-grade serous ovarian cancer","volume":"72","author":"Berns","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0030","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0035","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0040","first-page":"311","article-title":"Targeted therapies: a new generation of cancer treatments","volume":"77","author":"Gerber","year":"2008","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0045","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0050","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2165\/11591740-000000000-00000","article-title":"Molecular targeted therapy in ovarian cancer: what is on the horizon?","volume":"71","author":"Kalachand","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0055","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ctrv.2011.11.009","article-title":"Biomarkers in the development of anti-angiogenic therapies for ovarian cancer","volume":"38","author":"Raja","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrm1549","article-title":"Focal adhesion kinase: in command and control of cell motility","volume":"6","author":"Mitra","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0065","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ceb.2006.08.011","article-title":"Integrin-regulated FAK-Src signaling in normal and cancer cells","volume":"18","author":"Mitra","year":"2006","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0070","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P","article-title":"Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma","volume":"86","author":"Judson","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0075","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0002-9440(10)63370-6","article-title":"Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion","volume":"165","author":"Sood","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10585-012-9562-5","article-title":"Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression","volume":"30","author":"Ward","year":"2013","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0085","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1158\/1078-0432.CCR-05-1728","article-title":"Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells","volume":"11","author":"Halder","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0090","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1158\/0008-5472.CAN-07-2667","article-title":"Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma","volume":"67","author":"Halder","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0095","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4161\/cbt.9.10.11434","article-title":"PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments","volume":"9","author":"Tanjoni","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0100","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4161\/cbt.9.10.11433","article-title":"Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models","volume":"9","author":"Walsh","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0105","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1517\/13543784.2010.489548","article-title":"Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer","volume":"19","author":"Schultze","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0110","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2011.38.9346","article-title":"Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors","volume":"30","author":"Infante","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research N","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0120","first-page":"400","article-title":"Merlin: the wizard requires protein stability to function as a tumor suppressor","volume":"2012","author":"Morrow","year":"1826","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0125","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/embor.2012.11","article-title":"Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus","volume":"13","author":"Li","year":"2012","journal-title":"EMBO Rep"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0130","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0135","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/0008-5472.CAN-07-5155","article-title":"Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271","volume":"68","author":"Roberts","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1757-2215-3-24","article-title":"Development of a syngeneic mouse model of epithelial ovarian cancer","volume":"3","author":"Quinn","year":"2010","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molcel.2007.11.031","article-title":"Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation","volume":"29","author":"Lim","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0150","first-page":"197","article-title":"Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients","volume":"19","author":"Gyorffy","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0160","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1242\/jcs.045112","article-title":"Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions","volume":"123","author":"Schaller","year":"2010","journal-title":"J Cell Sci"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0165","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0002-9440(10)63058-1","article-title":"Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids","volume":"159","author":"Casey","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0170","first-page":"472","article-title":"Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features","volume":"5","author":"Taskin","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0175","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","article-title":"Development of a syngeneic mouse model for events related to ovarian cancer","volume":"21","author":"Roby","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0180","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-12-0388","article-title":"RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas","volume":"3","author":"Konstantinidou","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0185","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1083\/jcb.201307067","article-title":"Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function","volume":"204","author":"Jean","year":"2014","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ygyno.2014.04.044_bb0190","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ctrv.2013.01.002","article-title":"HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials","volume":"39","author":"Dent","year":"2013","journal-title":"Cancer Treat Rev"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814009056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814009056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:34:51Z","timestamp":1758771291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814009056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0090825814009056"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.04.044","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyses of merlin\/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.04.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}